Biomarin Pharmaceutical Inc
Change company Symbol lookup
Select an option...
BMRN Biomarin Pharmaceutical Inc
KRE SPDR® S&P Regional Banking ETF
CTOS Custom Truck One Source Inc
NYMT New York Mortgage Trust Inc
ABNB Airbnb Inc
ABBV Abbvie Inc
ABB Abb Ltd
AAPL Apple Inc
AAL American Airlines Group Inc
AA Alcoa Corp
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company’s portfolio consists of commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. The Company's commercial products include Aldurazyme (laronidase), Brineura (cerliponase alfa), Kuvan (sapropterin dihydrochloride), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Vimizim (elosulfase alpha) and Voxzogo (vosoritide). The Company's pipeline includes Valoctocogene Roxaparvovec for Severe Hemophilia A, Vosoritide for Achondroplasia, BMN 307 for Phenylketonuria (PKU) and BMN 331 for Hereditary Angioedema (HAE).

Postmarket

Last Trade
Delayed
$83.90
-0.75 (-0.89%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$84.65
Day's Change
0.20 (0.24%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
85.06
Day's Low
83.57
Volume
(Below Average)
Volume:
1,450,918

10-day average volume:
1,659,827
1,450,918

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.